Are comorbidities and previous antiretroviral therapyassociated with renal dysfunction in patients with HIV infectiontreated with tenofovir-based regimen?
Main Article Content
Keywords
renal failure, ntiretroviral therapy, risk factors
Abstract
Background: TLD, Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)/ dolutegravir (DTG), is one of the antiretroviral therapy (ART) for patients with HIV infection and can be used as the first-line treatment. The main concern of TLD is renal dysfunction. However, there is limited data if any comorbidities or previous ART was associated with renal dysfunction in patients with HIV infection treated with TLD. Objective: To evaluate if any comorbidities or previous ART associated with renal dysfunction in this setting. Methods: This study was a retrospective cohort study. The inclusion criteria were adult patients diagnosed as HIV infection, received treatment with TLD for at least 12 months, and had regular follow-up. The primary outcome was a decline of eGFR of 25% or more after treatment with TLD for 12 months. Factors associated with the primary outcome were computed by using logistic regression analysis. Results: There were 1,340 patients met the study criteria. Of those, 461 patients (34.40%) had eGFR decline of 25% or more after TLD treatment for 12 months. Four factors were significantly related with eGFR decline of 25% or more: naïve patient with TDF, and previous treatment with TDFFTCEFV (TEEVIR), AZT3TCNVP (GPOZ), and AZT3TCEFV. Previous treatment with AZT3TCEFV had the highest adjusted odds ratio of 2.992 (95% confidence interval of 1.682, 5.322), while TDFFTCEFV (TEEVIR) and AZT3TCNVP (GPOZ) had the adjusted odds ratio of 1.898 and 1.967, respectively. Conclusions: The prevalence of eGFR decline of 25% or more after TLD treatment for 12 months was 34.40%. Risk factors for eGFR decline of 25% or more included naïve patients to TLD or previously treated with tenofovir-based or zidovudine-based regimens.
References
2. Mahale PR, Patel BS, Kasmani N. Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV. Cureus 2023;15:e40139.
3. Keene CM, Griesel R, Zhao Y, Gcwabe Z, Sayed K, Hill A, Cassidy T, Ngwenya O, Jackson A, Van Zyl G, Schutz C, Goliath R, Flowers T, Goemaere E, Wiesner L, Simmons B, Maartens G, Meintjes G. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study. AIDS 2021;35:1423–32.
4. Tanuma J, Jiamsakul A, Makane A, Avihingsanon A, Ng OT, Kiertiburanakul S, Chaiwarith R, Kumarasamy N, Nguyen KV, Pham TT, Lee MP, Ditangco R, Merati TP, Choi JY, Wong WW, Kamarulzaman A, Yunihastuti E, Sim BL, Ratanasuwan W, Kantipong P, Zhang F, Mustafa M, Saphonn V, Pujari S, Sohn AH, TREAT Asia HIV Observational Databases (TAHOD). Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific. PLoS One 2016;11:e0161562.
5. Srisopa S, Kornjirakasemsan A, Treebupachatsakul P, Sonthisombat P. Incidence and Risk Factors of Tenofovir Disoproxil Fumarate Induced Nephrotoxicity and Renal Function Recovery, a Hospital Case-Control Study. Infect Chemother 2023;55:226– 36.
6. Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med 2018;19:817.
7. Kumarasamy N, Sundaram S, Poongulali S, Ezhilarasi C, Pradeep A, Chitra D. Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India. J Virus Erad n.d.;4:37–40.
8. Sacdalan C, Austin C, Varma A, Pinyakorn S, Kroon E, Colby DJ, Chan P, Goh O, Pornpaisakul K, Intasan J, Luekasemsuk T, Robb ML, Chomchey N, Phanuphak N, Ananworanich J, Vasan S, Hsu D, SEARCH 010/RV254 study group. Impaired creatinine-based estimated glomerular filtration rate in Thai individuals switching to dolutegravir: illustrating the role of cystatin C testing to aid clinical decision making. AIDS Res Ther 2025;22:15.
9. Izzedine H, Launay-Vacher V, Deray G. Antiviral Drug-Induced Nephrotoxicity. American Journal of Kidney Diseases 2005;45:804– 17.
10. Offor U, Ajayi SA, Jegede IA, Kharwa S, Naidu EC, Azu OO. Renal histoarchitectural changes in nevirapine therapy: possible role of kolaviron and vitamin C in an experimental animal model. Afr Health Sci 2017;17:164–74.
11. Wyatt CM, Klotman PE. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opin Drug Saf 2006;5:275–87.
12. Wyatt CM, Rodriguez-Caprio G, Klotman PE. Efavirenz: innocent bystander or direct nephrotoxin? AIDS 2007;21:1393.
13. Angel-Moreno-Maroto A, Suárez-Castellano L, Hernández-Cabrera M, Pérez-Arellano J-L. Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. Journal of Infection 2006;52:e39–40.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.